PDSB
PDS Biotechnology Corporation
Price Chart
Latest Quote
$0.94
-0.01 (-1.45%)
Current Price
| Previous Close | $0.95 |
| Open | $0.94 |
| Day High | $0.98 |
| Day Low | $0.93 |
| Volume | 361,030 |
Stock Information
| Shares Outstanding | 55.82M |
| Total Debt | $15.86M |
| Cash Equivalents | $21.66M |
| Net Income | $-33.36M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $52.53M |
| EPS (TTM) | $-0.66 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $47.50M |
| Income | $-33.36M |
| Book/sh | $0.17 |
| Cash/sh | $0.39 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 2.13 |
| Current Ratio | 2.25 |
| Debt/Eq | 407.47 |
Returns & Margins
| ROA | -50.49% |
| ROE | -254.09% |
Ownership
| Insider Ownership | 1.51% |
| Institutional Ownership | 9.16% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.02 |
| P/B | 5.57 |
Analyst Data
| Recommendation | none |
| Target Price | $7.50 |
Technical Indicators
| SMA20 | $1.06 |
| SMA50 | $1.11 |
| SMA200 | $0.93 |
| RSI | 38.32 |
| ATR | 0.1156 |
| Shares Float | 54.40M |
| Short Float | 3.26% |
| Short Ratio | 1.69 |
| Volatility | 1.56 |
| Rel Volume | 0.36 |
Performance History
| Week | -10.36% |
| Month | -8.62% |
| Quarter | +64.83% |
| 6 Months | +8.68% |
| YTD | +12.99% |
| Year | -41.54% |
| 3 Years | -84.25% |
| 5 Years | -92.68% |
| 10 Years | -99.52% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $0.94 | 361,030 |
| 2026-06-18 | $0.95 | 457,600 |
| 2026-06-17 | $0.91 | 659,800 |
| 2026-06-16 | $0.96 | 1,359,200 |
| 2026-06-15 | $1.02 | 1,148,900 |
| 2026-06-12 | $1.05 | 447,600 |
| 2026-06-11 | $1.12 | 593,400 |
| 2026-06-10 | $1.06 | 998,500 |
| 2026-06-09 | $1.03 | 922,700 |
| 2026-06-08 | $1.00 | 649,500 |
| 2026-06-05 | $1.02 | 1,606,600 |
| 2026-06-04 | $1.22 | 1,178,400 |
| 2026-06-03 | $1.08 | 751,800 |
| 2026-06-02 | $1.16 | 1,087,400 |
| 2026-06-01 | $1.14 | 1,448,400 |
| 2026-05-29 | $1.08 | 826,600 |
| 2026-05-28 | $1.07 | 2,254,200 |
| 2026-05-27 | $1.11 | 921,000 |
| 2026-05-26 | $1.10 | 987,200 |
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
đ° Latest News
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
Zacks âĸ 2026-06-10T13:55:02Z
PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...
GuruFocus.com âĸ 2026-05-13T23:02:39ZPDS Biotechnology Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T18:09:25Z
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T16:52:30Z
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
Benzinga âĸ 2026-05-13T12:26:11Z
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-31T12:30:00Z
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ...
GuruFocus.com âĸ 2026-03-31T01:01:54ZPDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
Zacks âĸ 2025-12-08T17:00:02Z
PDS Biotechnology price target lowered to $3 from $5 at B. Riley
TipRanks âĸ 2025-11-26T13:40:54Z
PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com âĸ 2025-11-13T19:06:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $5,338,607 | $4,673,174 | $4,205,922 | $1,316,519 |
| Total Expenses | $31,543,959 | $36,321,195 | $43,045,234 | $41,672,421 |
| Net Non Operating Interest Income Expense | $-4,121,366 | $-2,158,358 | $-1,302,983 | $-381,339 |
| Interest Expense Non Operating | $5,338,607 | $4,673,174 | $4,205,922 | $1,316,519 |
| Operating Expense | $31,543,959 | $36,321,195 | $43,045,234 | $41,672,421 |
| General And Administrative Expense | $12,518,127 | $13,755,671 | $15,282,450 | $12,241,394 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Net Interest Income | $-4,121,366 | $-2,158,358 | $-1,302,983 | $-381,339 |
| Interest Income | $1,217,241 | $2,514,816 | $2,902,939 | $935,180 |
| Normalized Income | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Net Income From Continuing And Discontinued Operation | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Total Operating Income As Reported | $-31,543,959 | $-36,321,195 | $-43,045,234 | $-41,672,421 |
| Net Income Common Stockholders | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Net Income | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Net Income Including Noncontrolling Interests | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Net Income Continuous Operations | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Pretax Income | $-35,665,325 | $-38,479,553 | $-44,348,217 | $-42,053,760 |
| Interest Income Non Operating | $1,217,241 | $2,514,816 | $2,902,939 | $935,180 |
| Operating Income | $-31,543,959 | $-36,321,195 | $-43,045,234 | $-41,672,421 |
| Per Share | ||||
| Diluted EPS | $-0.74 | $-1.03 | $-1.39 | $-1.43 |
| Basic EPS | $-0.74 | $-1.03 | $-1.39 | $-1.43 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-30,304,882 | $-33,785,267 | $-40,124,936 | $-40,737,155 |
| Reconciled Depreciation | $21,836 | $21,112 | $17,359 | $86 |
| EBITDA (Bullshit earnings) | $-30,304,882 | $-33,785,267 | $-40,124,936 | $-40,737,155 |
| EBIT | $-30,326,718 | $-33,806,379 | $-40,142,295 | $-40,737,241 |
| Diluted Average Shares | $46,384,280 | $36,452,707 | $30,952,060 | $28,599,221 |
| Basic Average Shares | $46,384,280 | $36,452,707 | $30,952,060 | $28,599,221 |
| Diluted NI Availto Com Stockholders | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Tax Provision | $-1,169,820 | $-869,169 | $-1,406,019 | $-1,198,905 |
| Research And Development | $19,025,832 | $22,565,524 | $27,762,784 | $29,431,027 |
| Selling General And Administration | $12,518,127 | $13,755,671 | $15,282,450 | $12,241,394 |
| Other Gand A | $12,518,127 | $13,755,671 | $15,282,450 | $12,241,394 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $9,251,833 | $19,004,848 | $26,130,947 | $44,002,030 |
| Total Assets | $30,494,083 | $45,358,657 | $59,390,080 | $77,007,923 |
| Total Non Current Assets | $2,239,998 | $304,214 | $335,005 | $527,533 |
| Non Current Prepaid Assets | $1,996,300 | $0 | - | - |
| Current Assets | $28,254,085 | $45,054,443 | $59,055,075 | $76,480,390 |
| Other Current Assets | $1,542,116 | $3,364,852 | $2,494,558 | $2,660,230 |
| Cash Cash Equivalents And Short Term Investments | $26,711,969 | $41,689,591 | $56,560,517 | $73,820,160 |
| Cash And Cash Equivalents | $26,711,969 | $41,689,591 | $56,560,517 | $73,820,160 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $16,925,575 | $21,827,727 | $23,851,617 | $23,472,898 |
| Long Term Debt And Capital Lease Obligation | $11,759,036 | $9,266,608 | $19,629,156 | $23,184,857 |
| Long Term Debt | $11,733,350 | $9,204,755 | $19,506,183 | $23,020,844 |
| Current Debt And Capital Lease Obligation | $5,166,539 | $12,561,119 | $4,222,461 | $288,041 |
| Current Debt | $5,130,372 | $12,500,000 | $4,166,667 | - |
| Other Current Borrowings | $5,130,372 | $12,500,000 | $4,166,667 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,242,250 | $26,353,809 | $33,259,133 | $33,005,893 |
| Total Non Current Liabilities Net Minority Interest | $11,759,036 | $9,266,608 | $19,629,156 | $23,184,857 |
| Current Liabilities | $9,483,214 | $17,087,201 | $13,629,977 | $9,821,036 |
| Payables And Accrued Expenses | $4,044,933 | $3,862,683 | $8,117,826 | $7,695,665 |
| Interest Payable | $0 | $252,322 | $306,771 | $280,382 |
| Payables | $3,574,448 | $1,684,868 | $6,982,824 | $1,219,287 |
| Accounts Payable | $3,574,448 | $1,684,868 | $6,982,824 | $1,219,287 |
| Equity | ||||
| Common Stock Equity | $9,251,833 | $19,004,848 | $26,130,947 | $44,002,030 |
| Total Equity Gross Minority Interest | $9,251,833 | $19,004,848 | $26,130,947 | $44,002,030 |
| Stockholders Equity | $9,251,833 | $19,004,848 | $26,130,947 | $44,002,030 |
| Retained Earnings | $-216,606,504 | $-182,110,999 | $-144,500,615 | $-101,558,417 |
| Other | ||||
| Ordinary Shares Number | $54,878,233 | $37,987,380 | $33,094,521 | $30,170,317 |
| Share Issued | $54,878,233 | $37,987,380 | $33,094,521 | $30,170,317 |
| Tangible Book Value | $9,251,833 | $19,004,848 | $26,130,947 | $44,002,030 |
| Invested Capital | $26,115,555 | $40,709,603 | $49,803,797 | $67,022,874 |
| Working Capital | $18,770,871 | $27,967,242 | $45,425,098 | $66,659,354 |
| Capital Lease Obligations | $61,853 | $122,972 | $178,767 | $452,054 |
| Total Capitalization | $20,985,183 | $28,209,603 | $45,637,130 | $67,022,874 |
| Additional Paid In Capital | $225,840,226 | $201,103,311 | $170,620,641 | $145,550,491 |
| Capital Stock | $18,111 | $12,536 | $10,921 | $9,956 |
| Common Stock | $18,111 | $12,536 | $10,921 | $9,956 |
| Long Term Capital Lease Obligation | $25,686 | $61,853 | $122,973 | $164,013 |
| Current Capital Lease Obligation | $36,167 | $61,119 | $55,794 | $288,041 |
| Pensionand Other Post Retirement Benefit Plans Current | $271,742 | $663,399 | $1,289,690 | $1,837,330 |
| Current Accrued Expenses | $470,485 | $2,177,815 | $1,135,002 | $6,476,378 |
| Net PPE | $243,698 | $304,214 | $335,005 | $527,533 |
| Accumulated Depreciation | $-175,727 | $-153,891 | $-132,779 | $-115,420 |
| Gross PPE | $419,425 | $458,105 | $467,784 | $642,953 |
| Other Properties | $390,916 | $429,596 | $439,275 | $461,799 |
| Machinery Furniture Equipment | $28,509 | $28,509 | $28,509 | $28,509 |
| Buildings And Improvements | - | - | $0 | $152,645 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-27,752,012 | $-35,059,223 | $-33,636,136 | $-25,709,706 |
| Operating Activities | ||||
| Operating Cash Flow | $-27,752,012 | $-35,030,223 | $-33,636,136 | $-25,709,706 |
| Cash Flow From Continuing Operating Activities | $-27,752,012 | $-35,030,223 | $-33,636,136 | $-25,709,706 |
| Operating Gains Losses | $1,107,004 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-29,000 | $0 | - |
| Cash Flow From Continuing Investing Activities | $0 | $-29,000 | $0 | - |
| Capital Expenditure | - | $-29,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $13,983,376 | $22,595,001 | $16,126,851 | $9,856,116 |
| Financing Cash Flow | $12,774,390 | $20,188,297 | $16,376,493 | $34,287,244 |
| Cash Flow From Continuing Financing Activities | $12,774,390 | $20,188,297 | $16,376,493 | $34,287,244 |
| Net Common Stock Issuance | $13,983,376 | $22,595,001 | $16,126,851 | $9,856,116 |
| Common Stock Issuance | $13,983,376 | $22,595,001 | $16,126,851 | $9,856,116 |
| Net Other Financing Charges | - | - | - | $-720,288 |
| Other | ||||
| Repayment Of Debt | $-25,727,786 | $-3,180,795 | $-59,300 | $0 |
| Issuance Of Debt | $18,164,795 | $0 | $0 | $25,000,000 |
| Interest Paid Supplemental Data | $2,921,359 | $3,556,662 | $3,535,071 | $852,221 |
| End Cash Position | $26,711,969 | $41,689,591 | $56,560,517 | $73,820,160 |
| Beginning Cash Position | $41,689,591 | $56,560,517 | $73,820,160 | $65,242,622 |
| Changes In Cash | $-14,977,622 | $-14,870,926 | $-17,259,643 | $8,577,538 |
| Proceeds From Stock Option Exercised | $6,354,005 | $774,091 | $308,942 | $151,416 |
| Net Issuance Payments Of Debt | $-7,562,991 | $-3,180,795 | $-59,300 | $25,000,000 |
| Net Long Term Debt Issuance | $-7,562,991 | $-3,180,795 | $-59,300 | $25,000,000 |
| Long Term Debt Payments | $-25,727,786 | $-3,180,795 | $-59,300 | $0 |
| Long Term Debt Issuance | $18,164,795 | $0 | $0 | $25,000,000 |
| Net PPE Purchase And Sale | $0 | $-29,000 | $0 | - |
| Purchase Of PPE | $0 | $-29,000 | $0 | - |
| Change In Working Capital | $-382,971 | $-5,751,728 | $-199,276 | $4,474,984 |
| Change In Other Current Liabilities | $0 | $0 | $-239,469 | $-74,363 |
| Change In Payables And Accrued Expense | $-209,407 | $-4,881,434 | $-125,479 | $6,035,888 |
| Change In Accrued Expense | $-2,098,987 | $416,522 | $-5,889,016 | $6,126,004 |
| Change In Payable | $1,889,580 | $-5,297,956 | $5,763,537 | $-90,116 |
| Change In Account Payable | $1,889,580 | $-5,297,956 | $5,763,537 | $-90,116 |
| Change In Prepaid Assets | $-173,564 | $-870,294 | $165,672 | $-1,062,661 |
| Other Non Cash Items | $1,891,018 | $1,462,584 | $1,873,658 | $5,473,923 |
| Stock Based Compensation | $4,106,606 | $6,848,193 | $7,614,321 | $5,196,156 |
| Depreciation Amortization Depletion | $21,836 | $21,112 | $17,359 | $86 |
| Depreciation And Amortization | $21,836 | $21,112 | $17,359 | $86 |
| Depreciation | $21,836 | $21,112 | $17,359 | $86 |
| Net Income From Continuing Operations | $-34,495,505 | $-37,610,384 | $-42,942,198 | $-40,854,855 |
| Change In Other Current Assets | - | - | $0 | $-423,880 |
Fetched: 2026-06-20